{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T12:58:23Z","timestamp":1751547503086,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s12328-024-01931-0","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T10:02:39Z","timestamp":1708682559000},"page":"451-456","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Conversion therapy with pembrolizumab for a peritoneal metastasis of rectal cancer causing hydronephrosis in a patient with Lynch syndrome"],"prefix":"10.1007","volume":"17","author":[{"given":"Akio","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0524-236X","authenticated-orcid":false,"given":"Yoshifumi","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mae","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikaru","family":"Ozeki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Yamai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumio","family":"Ishizaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Nyuzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Ikeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Wakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"1931_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0278","volume":"3","author":"G Tomasello","year":"2017","unstructured":"Tomasello G, Petrelli F, Ghidini M, et al. FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: a systematic review and pooled analysis. JAMA Oncol. 2017;3: e170278.","journal-title":"JAMA Oncol"},{"key":"1931_CR2","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1245\/s10434-015-4460-0","volume":"23","author":"Y Maeda","year":"2016","unstructured":"Maeda Y, Shinohara T, Nagatsu A, et al. Long-term outcomes of conversion hepatectomy for initially unresectable colorectal liver metastases. Ann Surg Oncol. 2016;23:242\u20138.","journal-title":"Ann Surg Oncol"},{"key":"1931_CR3","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/annonc\/mdi092","volume":"16","author":"T Delaunoit","year":"2005","unstructured":"Delaunoit T, Alberts SR, Sargent DJ, et al. Chemotherapy permits resection of metastatic colorectal cancer: experience from intergroup N9741. Ann Oncol. 2005;16:425\u20139.","journal-title":"Ann Oncol"},{"key":"1931_CR4","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","volume":"17","author":"J Franko","year":"2016","unstructured":"Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17:1709\u201319.","journal-title":"Lancet Oncol"},{"key":"1931_CR5","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/jso.27175","volume":"127","author":"T Aiken","year":"2023","unstructured":"Aiken T, Hu CY, Uppal A, et al. Peritoneal recurrence after resection for stage I\u2013III colorectal cancer: a population analysis. J Surg Oncol. 2023;127:678\u201387.","journal-title":"J Surg Oncol"},{"key":"1931_CR6","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1007\/s00535-013-0820-3","volume":"49","author":"H Kobayashi","year":"2014","unstructured":"Kobayashi H, Kotake K, Funahashi K, et al. Clinical benefit of surgery for stage IV colorectal cancer with synchronous peritoneal metastasis. J Gastroenterol. 2014;49:646\u201354.","journal-title":"J Gastroenterol"},{"key":"1931_CR7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1245\/s10434-017-6133-7","volume":"25","author":"D Shida","year":"2018","unstructured":"Shida D, Tsukamoto S, Ochiai H, et al. Long-term outcomes after R0 resection of synchronous peritoneal metastasis from colorectal cancer without cytoreductive surgery or hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2018;25:173\u20138.","journal-title":"Ann Surg Oncol"},{"key":"1931_CR8","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","volume":"15","author":"VJ Verwaal","year":"2008","unstructured":"Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15:2426\u201332.","journal-title":"Ann Surg Oncol"},{"key":"1931_CR9","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1200\/JCO.2008.19.7160","volume":"27","author":"D Elias","year":"2009","unstructured":"Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681\u20135.","journal-title":"J Clin Oncol"},{"key":"1931_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:10\u201332.","journal-title":"Ann Oncol"},{"key":"1931_CR11","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1038\/bjc.2013.82","volume":"108","author":"AG Kerscher","year":"2013","unstructured":"Kerscher AG, Chua TC, Gasser M, et al. Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades. Br J Cancer. 2013;108:1432\u20139.","journal-title":"Br J Cancer"},{"key":"1931_CR12","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1200\/JCO.2011.37.1039","volume":"30","author":"J Franko","year":"2012","unstructured":"Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of North Central Cancer Treatment Group Phase III trials N9741 and N9841. J Clin Oncol. 2012;30:263\u20137.","journal-title":"J Clin Oncol"},{"key":"1931_CR13","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","volume":"23","author":"LA Diaz","year":"2022","unstructured":"Diaz LA, Shiu K-K, Kim T-W, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022;23:659\u201370.","journal-title":"Lancet Oncol"},{"key":"1931_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1200\/JCO.21.01015","volume":"40","author":"H-J Lenz","year":"2022","unstructured":"Lenz H-J, Van Cutsem E, Luisa Limon M, et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J Clin Oncol. 2022;40:161\u201370.","journal-title":"J Clin Oncol"},{"key":"1931_CR15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ejca.2023.02.016","volume":"186","author":"DT Le","year":"2023","unstructured":"Le DT, Diaz LA Jr, Kim TW, et al. Pembrolizumab for previously treated, microsatellite instability-high\/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164. Eur J Cancer. 2023;186:185\u201395.","journal-title":"Eur J Cancer"},{"key":"1931_CR16","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18:1182\u201391.","journal-title":"Lancet Oncol"},{"key":"1931_CR17","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1663108","volume":"8","author":"J Zhang","year":"2019","unstructured":"Zhang J, Cai J, Deng Y, et al. Complete response in patients with locally advanced rectal cancer after neoadjuvant treatment with nivolumab. Oncoimmunology. 2019;8: e1663108.","journal-title":"Oncoimmunology"},{"key":"1931_CR18","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair\u2013deficient, locally advanced rectal cancer. N Engl J Med. 2022;386:2363\u201376.","journal-title":"N Engl J Med"},{"key":"1931_CR19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1159\/000487814","volume":"63","author":"M Baimas-George","year":"2018","unstructured":"Baimas-George M, Baker E, Kamionek M, et al. A complete pathological response to pembrolizumab following ex vivo liver resection in a patient with colorectal liver metastases. Chemotherapy. 2018;63:90\u20134.","journal-title":"Chemotherapy"},{"key":"1931_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12876-021-02084-x","volume":"22","author":"M Tonello","year":"2022","unstructured":"Tonello M, Nappo F, Vassallo L, et al. Complete pathological response of colorectal peritoneal metastases in Lynch syndrome after immunotherapy case report: is a paradigm shift in cytoreductive surgery needed? BMC Gastroenterol. 2022;22:17.","journal-title":"BMC Gastroenterol"},{"key":"1931_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijscr.2023.108286","volume":"106","author":"HG Smith","year":"2023","unstructured":"Smith HG, Bodilsen A, Rose L, et al. Challenges presented by complete response to immune checkpoint blockade in patients with dMMR colorectal cancer: a case report. Int J Surg Case Rep. 2023;106: 108286.","journal-title":"Int J Surg Case Rep"},{"key":"1931_CR22","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.2147\/OTT.S298333","volume":"14","author":"J Yang","year":"2021","unstructured":"Yang J, Bi F, Gou H. Complete pathologic response after concurrent treatment with pembrolizumab and radiotherapy in metastatic colorectal cancer: a case report. Onco Targets Ther. 2021;14:2555\u201361.","journal-title":"Onco Targets Ther"},{"key":"1931_CR23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3892\/ol.2022.13332","volume":"24","author":"S Igaue","year":"2022","unstructured":"Igaue S, Okuno T, Ishibashi H, et al. A pathological complete response after nivolumab plus ipilimumab therapy for DNA mismatch repair-deficient\/microsatellite instability-high metastatic colon cancer: a case report. Oncol Lett. 2022;24:211.","journal-title":"Oncol Lett"},{"key":"1931_CR24","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3892\/mco.2022.2539","volume":"16","author":"G Tong","year":"2022","unstructured":"Tong G, Chen B, Zhang M, et al. Treatment efficacy and prognosis analysis in locally advanced or metastatic colorectal cancer patients with hydronephrosis. Mol Clin Oncol. 2022;16:106.","journal-title":"Mol Clin Oncol"},{"key":"1931_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1308\/1478708051432","volume":"87","author":"JR Wilson","year":"2005","unstructured":"Wilson JR, Urwin GH, Stower MJ. The role of percutaneous nephrostomy in malignant ureteric obstruction. Ann R Coll Surg Engl. 2005;87:21\u20134.","journal-title":"Ann R Coll Surg Engl"},{"key":"1931_CR26","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1053\/ejso.2001.1143","volume":"27","author":"D Lev-Chelouche","year":"2001","unstructured":"Lev-Chelouche D, Keidar A, Rub R, et al. Hydronephrosis associated with colorectal carcinoma: treatment and outcome. Eur J Surg Oncol. 2001;27:482\u20136.","journal-title":"Eur J Surg Oncol"},{"key":"1931_CR27","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1245\/ASO.2005.10.004","volume":"12","author":"LR Henry","year":"2005","unstructured":"Henry LR, Sigurdson E, Ross E, et al. Hydronephrosis does not preclude curative resection of pelvic recurrences after colorectal surgery. Ann Surg Oncol. 2005;12:786\u201392.","journal-title":"Ann Surg Oncol"},{"unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colon cancer (version 4. 2023). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf. Accessed 10 Dec 2023.","key":"1931_CR28"},{"key":"1931_CR29","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Shiu K-K, Kim TW, et al. Pembrolizumab in microsatellite-instability\u2013high advanced colorectal cancer. N Engl J Med. 2020;383:2207\u201318.","journal-title":"N Engl J Med"},{"key":"1931_CR30","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1007\/s00259-016-3425-2","volume":"43","author":"E Lopci","year":"2016","unstructured":"Lopci E, Toschi L, Grizzi F, et al. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. Eur J Nucl Med Mol Imaging. 2016;43:1954\u201361.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1931_CR31","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s00259-018-4171-4","volume":"46","author":"N Aide","year":"2019","unstructured":"Aide N, Hicks RJ, Le Tourneau C, et al. FDG PET\/CT for assessing tumour response to immunotherapy. Eur J Nucl Med Mol Imaging. 2019;46:238\u201350.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1931_CR32","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1245\/s10434-015-4951-z","volume":"23","author":"HS Park","year":"2016","unstructured":"Park HS, Jung M, Shin SJ, et al. Benefit of adjuvant chemotherapy after curative resection of lung metastasis in colorectal cancer. Ann Surg Oncol. 2016;23:928\u201335.","journal-title":"Ann Surg Oncol"},{"key":"1931_CR33","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00384-023-04407-8","volume":"38","author":"K Noda","year":"2023","unstructured":"Noda K, Tominaga T, Nonaka T, et al. Effect of adjuvant chemotherapy after curative resection of colorectal cancer peritoneal metastasis. Int J Colorectal Dis. 2023;38:101.","journal-title":"Int J Colorectal Dis"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-024-01931-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-024-01931-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-024-01931-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T13:12:05Z","timestamp":1716642725000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-024-01931-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1931"],"URL":"https:\/\/doi.org\/10.1007\/s12328-024-01931-0","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"type":"print","value":"1865-7257"},{"type":"electronic","value":"1865-7265"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"assertion":[{"value":"26 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no current financial arrangement or affiliation with any organization which may have a direct influence on their work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was reviewed and approved by the Institutional Review Board of Niigata University (G2015-0816, G2020-0038).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and accompanying images.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no current financial arrangement or affiliation with any organization which may have a direct influence on their work.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}